Ozempic and Bone Density: What the 2026 AAOS Research Revealed

The AAOS 2026 Findings That Changed the Conversation

At the March 2026 American Academy of Orthopaedic Surgeons Annual Meeting in New Orleans, two major studies presented data that drew coverage in the Washington Post, NBC News, Medscape, and Medical News Today.

The combined message: GLP-1 receptor agonist users face dramatically elevated musculoskeletal risks — affecting bones, joints, and tendons — compared to matched controls.

Study 1: Bone, Gout, and Osteomalacia (Michigan State)

A team led by Muaaz Wajahath at Michigan State University College of Human Medicine analyzed electronic medical records for 146,966 adults with Type 2 diabetes and obesity (BMI ≥30 kg/m²). Patients on GLP-1 medications were matched 1:1 with controls (73,483 per group) and followed for five years.

Over that period, GLP-1 users showed:

|-----------|------------|----------|---------------|

All findings were statistically significant (p<0.001) and held after adjusting for age, sex, BMI, and comorbidities.

Study 2: Tendon Ruptures (UTMB)

A second study, presented by Jad Lawand of the University of Texas Medical Branch, analyzed 78,590 matched pairs of obese patients (157,180 total). The headline finding: GLP-1 users faced an approximately 50% higher relative risk of major tendon ruptures — including rotator cuff tears, Achilles tendon ruptures, and pectoralis major injuries.

The qualitative pattern is what concerns clinicians: many ruptures occurred during low-load activities — reaching forward, lifting light objects — not during sports or gym workouts. That signature suggests GLP-1 therapy may impair tendon integrity in ways that aren't apparent until the tissue fails under everyday strain.

What Is Osteomalacia?

While most people have heard of osteoporosis (brittle, porous bones), osteomalacia is less well-known but equally concerning. Osteomalacia is the softening of bones due to defective bone mineralization — often caused by severe vitamin D deficiency.

GLP-1 medications contribute to osteomalacia through:

A 2.55-fold increased risk means GLP-1 users in the Wajahath cohort were roughly two-and-a-half times more likely to develop bone softening than similar patients not on these medications.

Why Your Prescribing Doctor Probably Isn't Monitoring This

The honest answer: it's not their specialty. Endocrinologists and weight-loss clinics focus on metabolic markers — A1C, blood pressure, lipids, body weight. They're doing an excellent job managing the metabolic side of GLP-1 therapy.

But musculoskeletal health requires different expertise:

This is orthopedic medicine. And that's precisely why MetaOrtho exists.

What Should You Do?

If you've been on GLP-1 therapy for 3+ months:

If you're about to start GLP-1 therapy:

The Bigger Picture

GLP-1 medications are genuinely revolutionary drugs. They're saving lives, reducing cardiovascular events, and helping millions of people achieve weight loss that was previously impossible.

But like all powerful medications, they have side effects. The musculoskeletal effects are real and measurable, and proactive monitoring and intervention can meaningfully reduce their impact.

The question isn't whether to take GLP-1s. The question is: who is watching your bones, joints, and tendons while you lose weight?

References

Dr. Jay M. Saenz is a board-certified orthopedic surgeon and founder of MetaOrthopedics, a telehealth practice dedicated to musculoskeletal monitoring for GLP-1 patients.